The global colorectal cancer therapeutics market is anticipated to grow at a CAGR of 5.8% during the forecast period (2023-2030). The market growth is attributed to increasing number of grants to expand quality initiatives focused on enhancing biomarker-directed therapy in metastatic colorectal cancer. In August 2023, the National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) received the new grants to improve quality initiatives focused on optimizing biomarker-directed therapy in metastatic colorectal cancer. Fight Colorectal Cancer (Fight CRC) collaborated with NCCN and Pfizer, Inc in the grant process; Pfizer provided funding and oversee the projects.
Browse the full report description of “Colorectal Cancer Therapeutics Market Size, Share & Trends Analysis Report by Types of Colorectal Cancer (Colorectal adenocarcinoma, Gastrointestinal carcinoid tumors and Others), by Therapy (Immunotherapy, Chemotherapy, Radiation therapy, and Others), and by End-Use (Hospitals and Clinics), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/colorectal-cancer-therapeutics-market-size
Further, the growing FDA approvals and emergence of more front-line therapies are also contributing to the market growth. In January 19, 2023, the Food and Drug Administration (FDA) granted accelerated approval to tucatinib (Tukysa, Seagen Inc.) in combination with trastuzumab for RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. There are different mutations within BRAF, but the one with FDA-approved treatment in colorectal cancer is BRAF V600E. This mutation is a specific variation in the BRAF protein. In cells with this mutation, BRAF always turn on the MEK protein. In September 2021, Eli Lilly and Company received the US FDA granted approval of a new indication for ERBITUX® (cetuximab injection) in combination with BRAFTOVI® (encorafenib), marketed by Pfizer, Inc., for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Types of Colorectal Cancer
o By Therapy
o By End user
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
Competitive Landscape- includes, Eli Lilly and Co., Genentech, Inc., Ipsen Pharma, Regeneron Pharmaceuticals, Inc, F. Hoffmann-La Roche Ltd., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Colorectal Cancer Therapeutics Market Report Segment
By Types of colorectal cancer
By Therapy
By End-User
Global Colorectal Cancer Therapeutics Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/colorectal-cancer-therapeutics-market-size